Aktana, Inc v. Veeva Systems Inc.

Azurity Pharmaceuticals, Inc. et al.vsHeron Therapeutics, Inc.

Azurity has filed a PGR petition seeking cancellation of claims 1‑30 of Heron’s U.S. 12,115,254 patent covering injectable aprepitant emulsions. The petition alleges obviousness over four prior‑art references and asserts lack of written description and enablement due to overly broad claim ranges. Institution is requested and discretionary denial is contested.

PacifiCorp et al.vsMES, Inc.

Utility affiliates of Berkshire Hathaway Energy settled multiple PTAB IPRs, leading to the termination of the cases for the settling parties while the Board kept the proceedings open for the remaining petitioners.

Arashi Vision Inc. (d/b/a Insta360)vsGoPro, Inc.

The PTAB granted institution of IPR for Arashi Vision against GoPro, finding a reasonable likelihood that the '840 patent claims are obvious in view of Bell and Shi. The Board adopted a functional construction of the key parameter.

Samsung Electronics Co., Ltd. et al.vsOura Health Oy et al.

Samsung Electronics Co., Ltd. has filed a petition challenging Oura Health Oy's patent for a wearable computing device, arguing that the invention is unpatentable over existing prior art. The petitioner asserts that combining references such as Schröder and Yuen renders the claimed finger ring obvious, covering both anticipation (102) and obviousness (103).

Abbott Diabetes Care Inc. et al.vsDexCom, Inc.

Abbott Diabetes Care and DexCom settled their IPR dispute over U.S. Patent 9,801,541, filing a joint motion that led the PTAB to terminate the proceeding and keep the settlement agreement confidential.